A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

596

Participants

Timeline

Start Date

June 21, 2013

Primary Completion Date

April 22, 2016

Study Completion Date

December 26, 2021

Conditions
Ovarian NeoplasmsPlatinum Sensitive Ovarian Cancer
Interventions
DRUG

Active comparator: Niraparib

Niraparib vs placebo 2:1 ratio

DRUG

placebo

Trial Locations (112)

1090

GSK Investigational Site, Vienna

2650

GSK Investigational Site, Edegem

3000

GSK Investigational Site, Leuven

4000

GSK Investigational Site, Liège

5000

GSK Investigational Site, Odense

5004

GSK Investigational Site, Szolnok

5021

GSK Investigational Site, Bergen

8035

GSK Investigational Site, Barcelona

8500

GSK Investigational Site, Kortrijk

9100

GSK Investigational Site, Aalborg

10016

GSK Investigational Site, New York

10065

GSK Investigational Site, New York

11042

GSK Investigational Site, Lake Success

13353

GSK Investigational Site, Berlin

19111

GSK Investigational Site, Philadelphia

20133

GSK Investigational Site, Milan

20141

GSK Investigational Site, Milan

20246

GSK Investigational Site, Hamburg

24105

GSK Investigational Site, Kiel

25030

GSK Investigational Site, Besançon

25123

GSK Investigational Site, Brescia

27710

GSK Investigational Site, Durham

28033

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

30177

GSK Investigational Site, Hanover

30342

GSK Investigational Site, Atlanta

33011

GSK Investigational Site, Oviedo

33612

GSK Investigational Site, Tampa

34232

GSK Investigational Site, Sarasota

34298

GSK Investigational Site, Montpellier

37075

GSK Investigational Site, Göttingen

37203

GSK Investigational Site, Nashville

40217

GSK Investigational Site, Düsseldorf

44281

GSK Investigational Site, Kfar Saba

44805

GSK Investigational Site, Saint-Herblain

45122

GSK Investigational Site, Essen

45136

GSK Investigational Site, Essen

46202

GSK Investigational Site, Indianapolis

46260

GSK Investigational Site, Indianapolis

52621

GSK Investigational Site, Tel Litwinsky

55404

GSK Investigational Site, Minneapolis

55455

GSK Investigational Site, Minneapolis

55905

GSK Investigational Site, Rochester

58100

GSK Investigational Site, Holon

59000

GSK Investigational Site, Lille

60611

GSK Investigational Site, Chicago

64239

GSK Investigational Site, Tel Aviv

69120

GSK Investigational Site, Heidelberg

73104

GSK Investigational Site, Oklahoma City

75390

GSK Investigational Site, Dallas

76100

GSK Investigational Site, Rehovot

76104

GSK Investigational Site, Fort Worth

77380

GSK Investigational Site, The Woodlands

78731

GSK Investigational Site, Austin

81377

GSK Investigational Site, Munich

85013

GSK Investigational Site, Phoenix

85704

GSK Investigational Site, Tucson

87401

GSK Investigational Site, Farmington

90027

GSK Investigational Site, Los Angeles

90048

GSK Investigational Site, Los Angeles

91031

GSK Investigational Site, Jerusalem

91120

GSK Investigational Site, Jerusalem

94109

GSK Investigational Site, San Francisco

94304

GSK Investigational Site, Palo Alto

95126

GSK Investigational Site, Catania

98684

GSK Investigational Site, Vancouver

3109601

GSK Investigational Site, Haifa

06510

GSK Investigational Site, New Haven

02115

GSK Investigational Site, Boston

02215

GSK Investigational Site, Boston

01805

GSK Investigational Site, Burlington

07962-1956

GSK Investigational Site, Morristown

19001-3788

GSK Investigational Site, Abington

02905

GSK Investigational Site, Providence

A-8036

GSK Investigational Site, Graz

A-6020

GSK Investigational Site, Innsbruck

T2N 4N2

GSK Investigational Site, Calgary

V1Y 5L3

GSK Investigational Site, Kelowna

V5Z 4E6

GSK Investigational Site, Vancouver

M5G 2M9

GSK Investigational Site, Toronto

H2L 4M1

GSK Investigational Site, Montreal

H3T 1E2

GSK Investigational Site, Montreal

H4A 3J1

GSK Investigational Site, Montreal

J1H 5N4

GSK Investigational Site, Sherbrooke

DK-2100

GSK Investigational Site, Copenhagen

DK-2730

GSK Investigational Site, Herlev

06189

GSK Investigational Site, Nice

22015 cedex

GSK Investigational Site, Saint-Brieuc

01307

GSK Investigational Site, Dresden

00168

GSK Investigational Site, Rome

0379

GSK Investigational Site, Oslo

15-207

GSK Investigational Site, Bialystok

80-219

GSK Investigational Site, Gdansk

94-029

GSK Investigational Site, Lodz

60-569

GSK Investigational Site, Poznan

08907

GSK Investigational Site, Barcelona

07198

GSK Investigational Site, Palma de Mallorca

SE-581 85

GSK Investigational Site, Linköping

SE-221 85

GSK Investigational Site, Lund

SE-171 76

GSK Investigational Site, Stockholm

NG5 1PB

GSK Investigational Site, Nottingham

BA21 4AT

GSK Investigational Site, Yeovil

B18 7QH

GSK Investigational Site, Birmingham

CH63 4JY

GSK Investigational Site, Bebington, Wirral

NW1 2PG

GSK Investigational Site, London

SE1 9RT

GSK Investigational Site, London

SW3 6JJ

GSK Investigational Site, London

SW36JJ

GSK Investigational Site, London

ME16 9QQ

GSK Investigational Site, Maidstone

LL18 5UJ

GSK Investigational Site, Rhyl

TA1 5DA

GSK Investigational Site, Taunton

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

European Network of Gynaecological Oncological Trial Groups (ENGOT)

OTHER

collaborator

Myriad Genetics, Inc.

INDUSTRY

collaborator

US Oncology Research

INDUSTRY

collaborator

Sarah Cannon

INDUSTRY

collaborator

Cooperative Ovarian Cancer Group (COGI)

UNKNOWN

collaborator

Facing Our Risk of Cancer Empowered

OTHER

lead

Tesaro, Inc.

INDUSTRY

NCT01847274 - A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer | Biotech Hunter | Biotech Hunter